» Articles » PMID: 39273511

Crucial Parameters for Immunopeptidome Characterization: A Systematic Evaluation

Abstract

Immunopeptidomics is the area of knowledge focused on the study of peptides assembled in the major histocompatibility complex (MHC), or human leukocyte antigen (HLA) in humans, which could activate the immune response via specific and selective T cell recognition. Advances in high-sensitivity mass spectrometry have enabled the detailed identification and quantification of the immunopeptidome, significantly impacting fields like oncology, infections, and autoimmune diseases. Current immunopeptidomics approaches primarily focus on workflows to identify immunopeptides from HLA molecules, requiring the isolation of the HLA from relevant cells or tissues. Common critical steps in these workflows, such as cell lysis, HLA immunoenrichment, and peptide isolation, significantly influence outcomes. A systematic evaluation of these steps led to the creation of an 'Immunopeptidome Score' to enhance the reproducibility and robustness of these workflows. This score, derived from LC-MS/MS datasets (ProteomeXchange identifier PXD038165), in combination with available information from public databases, aids in optimizing the immunopeptidome characterization process. The 'Immunopeptidome Score' has been applied in a systematic analysis of protein extraction, HLA immunoprecipitation, and peptide recovery yields across several tumor cell lines enabling the selection of peptides with optimal features and, therefore, the identification of potential biomarker and therapeutic targets.

References
1.
Petersdorf E, OhUigin C . The MHC in the era of next-generation sequencing: Implications for bridging structure with function. Hum Immunol. 2018; 80(1):67-78. PMC: 6542361. DOI: 10.1016/j.humimm.2018.10.002. View

2.
Gomez-Zepeda D, Arnold-Schild D, Beyrle J, Declercq A, Gabriels R, Kumm E . Thunder-DDA-PASEF enables high-coverage immunopeptidomics and is boosted by MSRescore with MSPIP timsTOF fragmentation prediction model. Nat Commun. 2024; 15(1):2288. PMC: 10937930. DOI: 10.1038/s41467-024-46380-y. View

3.
June C, OConnor R, Kawalekar O, Ghassemi S, Milone M . CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382):1361-1365. DOI: 10.1126/science.aar6711. View

4.
RAMMENSEE H, Bachmann J, Emmerich N, Bachor O, Stevanovic S . SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999; 50(3-4):213-9. DOI: 10.1007/s002510050595. View

5.
Yu F, Haynes S, Teo G, Avtonomov D, Polasky D, Nesvizhskii A . Fast Quantitative Analysis of timsTOF PASEF Data with MSFragger and IonQuant. Mol Cell Proteomics. 2020; 19(9):1575-1585. PMC: 7996969. DOI: 10.1074/mcp.TIR120.002048. View